Published in Mayo Clin Proc on March 01, 2002
Tolerability and compliance with risedronate in clinical practice. Osteoporos Int (2003) 1.51
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int (2011) 1.50
Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial. Osteoporos Int (2007) 1.44
Canadian Consensus Conference on osteoporosis, 2006 update. J Obstet Gynaecol Can (2006) 1.33
Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int (2009) 1.14
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag (2010) 1.12
The role of bisphosphonates in diseases of childhood. Eur J Pediatr (2003) 0.89
Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review. Support Care Cancer (2008) 0.89
The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis. J Bone Miner Metab (2012) 0.88
Bisphosphonate use and subsequent prescription of acid suppressants. Br J Clin Pharmacol (2004) 0.86
Progress in osteoporosis and fracture prevention: focus on postmenopausal women. Arthritis Res Ther (2009) 0.85
Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations. MedGenMed (2004) 0.84
Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England. Osteoporos Int (2005) 0.82
Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies. Osteoporos Int (2003) 0.82
Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study. Osteoporos Int (2015) 0.80
Serum level of pepsinogen significantly associated with gastric distress induced by amino-bisphosphonates. Osteoporos Int (2010) 0.80
Oral bisphosphonates do not increase the risk of severe upper gastrointestinal complications: a nested case-control study. BMC Gastroenterol (2014) 0.78
Updates on mechanism of action and clinical efficacy of risedronate in osteoporosis. Clin Cases Miner Bone Metab (2014) 0.78
Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation. Int J Womens Health (2012) 0.76
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Clin Interv Aging (2009) 0.76
Risedronate's efficacy: from randomized clinical trials to real clinical practice. Clin Cases Miner Bone Metab (2010) 0.76
Upper gastrointestinal safety and tolerability of oral alendronate: A meta-analysis. Exp Ther Med (2015) 0.75
Bone fracture and the interaction between bisphosphonates and proton pump inhibitors: a meta-analysis. Int J Clin Exp Med (2015) 0.75
Risedronate's Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis. Clin Med Insights Arthritis Musculoskelet Disord (2012) 0.75
Risk of severe upper gastrointestinal complications among oral bisphosphonate users. PLoS One (2013) 0.75
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
Denosumab in postmenopausal women with low bone mineral density. N Engl J Med (2006) 10.02
2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ (2002) 9.89
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet (2002) 9.48
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA (2003) 8.47
Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med (2014) 6.56
Burn wound infections. Clin Microbiol Rev (2006) 4.81
The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein. Am J Clin Nutr (2008) 3.33
Effect of a low-glycemic index or a high-cereal fiber diet on type 2 diabetes: a randomized trial. JAMA (2008) 3.25
Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA (2003) 3.03
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum (2006) 2.82
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol (2006) 2.74
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res (2015) 2.74
American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract (2004) 2.69
Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res (2007) 2.68
Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ (2009) 2.64
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med (2007) 2.64
Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2008) 2.57
Effect of legumes as part of a low glycemic index diet on glycemic control and cardiovascular risk factors in type 2 diabetes mellitus: a randomized controlled trial. Arch Intern Med (2012) 2.54
Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med (2005) 2.47
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab (2008) 2.43
Generation Scotland: the Scottish Family Health Study; a new resource for researching genes and heritability. BMC Med Genet (2006) 2.25
The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol (2012) 2.24
Intensive blood pressure control, falls, and fractures in patients with type 2 diabetes: the ACCORD trial. J Gen Intern Med (2014) 2.20
Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J (2005) 2.15
Dialysate calcium concentration and mineral metabolism in long and long-frequent hemodialysis: a systematic review and meta-analysis for a Canadian Society of Nephrology clinical practice guideline. Am J Kidney Dis (2013) 2.07
Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med (2011) 1.95
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res (2012) 1.92
Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2009) 1.90
Effect of wheat bran on glycemic control and risk factors for cardiovascular disease in type 2 diabetes. Diabetes Care (2002) 1.88
Survival with three-times weekly in-center nocturnal versus conventional hemodialysis. J Am Soc Nephrol (2012) 1.88
Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet (2013) 1.82
Low bone mineral density and fracture burden in postmenopausal women. CMAJ (2007) 1.81
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res (2005) 1.81
Direct comparison of a dietary portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic participants. Am J Clin Nutr (2005) 1.80
Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2012) 1.79
Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol (2002) 1.78
Autosomal dominant pseudohypoparathyroidism type Ib is associated with a heterozygous microdeletion that likely disrupts a putative imprinting control element of GNAS. J Clin Invest (2003) 1.77
Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res (2010) 1.74
Effective initiation of osteoporosis diagnosis and treatment for patients with a fragility fracture in an orthopaedic environment. J Bone Joint Surg Am (2006) 1.72
Effect of a low glycaemic index diet on blood glucose in women with gestational hyperglycaemia. Diabetes Res Clin Pract (2010) 1.71
Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab (2003) 1.65
Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. Mayo Clin Proc (2010) 1.62
Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res (2014) 1.62
Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab (2011) 1.59
Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom (2004) 1.59
Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol (2008) 1.55
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab (2008) 1.53
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med (2004) 1.51
The effect of combining plant sterols, soy protein, viscous fibers, and almonds in treating hypercholesterolemia. Metabolism (2003) 1.49
Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. CMAJ (2010) 1.45
Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. J Bone Miner Res (2002) 1.44
Males have larger skeletal size and bone mass than females, despite comparable body size. J Bone Miner Res (2004) 1.42
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2002) 1.41
Allergy and the bone: unexpected relationships. Ann Allergy Asthma Immunol (2011) 1.41
Structure of clean and adsorbate-covered single-crystal rutile TiO2 surfaces. Chem Rev (2013) 1.40
Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab (2003) 1.38
Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. J Clin Endocrinol Metab (2012) 1.38
Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis. J Bone Miner Res (2010) 1.37
Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res (2005) 1.33
Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res (2004) 1.32
Recognizing and reporting vertebral fractures: reducing the risk of future osteoporotic fractures. Can Assoc Radiol J (2007) 1.32
The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther (2004) 1.30
Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manag Care (2008) 1.30
Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res (2012) 1.29
Changes to osteoporosis prevalence according to method of risk assessment. J Bone Miner Res (2007) 1.28
Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. J Bone Miner Res (2012) 1.26
Chemical reactions on rutile TiO2(110). Chem Soc Rev (2008) 1.26
Association between BMI measured within a year after diagnosis of type 2 diabetes and mortality. Diabetes Care (2012) 1.25
A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res (2015) 1.23
Predicting fractures in an international cohort using risk factor algorithms without BMD. J Bone Miner Res (2011) 1.22
Relationship of weight, height, and body mass index with fracture risk at different sites in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW). J Bone Miner Res (2014) 1.19
Association between change in BMD and fragility fracture in women and men. J Bone Miner Res (2009) 1.19
Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab (2003) 1.19
Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol (2008) 1.18
Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children. J Clin Densitom (2004) 1.18
Long-term effects of amino-bisphosphonates on circulating γδ T cells. Calcif Tissue Int (2012) 1.18
Retracted Nuts as a replacement for carbohydrates in the diabetic diet. Diabetes Care (2011) 1.17
Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab (2009) 1.16
Vitamin D deficiency in rheumatoid arthritis: prevalence, determinants and associations with disease activity and disability. Arthritis Res Ther (2010) 1.16
Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment. J Clin Densitom (2007) 1.15
Effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab (2009) 1.13
Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab (2010) 1.12
Adding monounsaturated fatty acids to a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia. CMAJ (2010) 1.12
Relation of lower-extremity amputation to all-cause and cardiovascular disease mortality in American Indians: the Strong Heart Study. Diabetes Care (2004) 1.12
Health professional's guide to rehabilitation of the patient with osteoporosis. Osteoporos Int (2003) 1.11
Osteoporosis Canada 2010 guidelines for the assessment of fracture risk. Can Assoc Radiol J (2011) 1.11
Usability of a pre-filled insulin injection device in a 3-month observational survey of everyday clinical practice in Australia. Curr Med Res Opin (2008) 1.10
Precision, accuracy, and reproducibility of dual X-ray absorptiometry measurements in mice in vivo. J Clin Densitom (2003) 1.10